Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Biosimilars Companies

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing FDA-approved reference biologic products. These drugs are designed to mimic the therapeutic effects of the original biologic drugs but are usually produced by different manufacturers.

Biosimilars Key Companies Latest Biosimilars Companies Update

January 2023: the public will be able to purchase a biosimilar version of Humira, a medication for rheumatoid arthritis, from Amgen, the biggest pharmaceutical business in the world. The prescription drug coverage provisions of the customer's health insurance policy will decide the out-of-pocket payments. Even though AbbVie's Humira generated over $20 billion in sales last year, a slew of biosimilars, spearheaded by Amjevita, are set to hit the market this year, posing a serious threat to the popular medicine.

Lannett Company, Inc. updated investors on the research and clinical status of its insulin glargine and insulin aspart biosimilars. For the creation of both items, Lannett formed a strategic collaboration with the HEC Group of Companies (HEC). Subcutaneous administration of equivalent amounts of the reference biologic, US NovoLog®, and the Lannett/HEC biosimilar insulin aspart showed very similar results in a trial conducted by the business.

March 2023: Eli Lilly and Company will launch Rezvoglar, a biosimilar insulin glargine that may be used interchangeably, at a 78% reduction compared to the original (Lantus). Rezvolgar, also known as insulin glargine-aglr, became the fourth biosimilar to be granted interchangeability certification in November 2022. After Semglee (insulin glargine-yfgn), which was approved by the FDA in December 2021, this was the second insulin biosimilar to get the interchangeability label. The insulin lispro reference drug Humalog, the recombinant human insulin Humulin, and an unbranded insulin lispro product are all manufactured by Lilly. Rezvoglar is one of these products.

List of Biosimilars Key companies in the market

Pfizer (US)

Sandoz (Germany)

Biocon (India)

Biogen (US)

Fresenius Kabi AG (Germany)

Boehringer Ingelheim (Germany)

Merck KgaA (Germany)

Mylan (US)

Eli Lilly (US)

Teva Pharmaceutical (Israel)

Biosimilars Market Highlights:

Biosimilars Market Size

Biosimilars Market Trends

Biosimilars Market Analysis

Biosimilars Market Share

Biosimilars Market Highlights:

Biosimilars Market Trends

Biosimilars Market Analysis

Biosimilars Market Share

Biosimilars Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.